Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Basis Of Presentation [Line Items]
Net Income (Loss)	$ (2,798)	$ (4,868)	$ (9,283)	$ (10,717)
Proceeds from the sale of common stock and pre-funded warrants, net of fees			2,786	8,502
Working capital	9,100		9,100		$ 5,200
Cash and cash equivalents	5,272		5,272		6,566
Accounts receivable, net	$ 4,842		$ 4,842		$ 5,483
Common Stock, Par or Stated Value Per Share	$ 0.001		$ 0.001		$ 0.001
Principal Payment On Loan			$ 865	0
Proceeds from disposal of property, plant, and equipment			284	$ 0
February 2024 Public Offering [Member]
Basis Of Presentation [Line Items]
Net Income (Loss)			(9,300)
Proceeds from the sale of common stock and pre-funded warrants, net of fees			5,800
Principal Payment On Loan			900
Proceeds from disposal of property, plant, and equipment			$ 300
2024 Annual Meeting [Member]
Basis Of Presentation [Line Items]
Common Stock, Par or Stated Value Per Share	0.001		$ 0.001
Reverse Stock Split			a reverse stock split of BIOLASE common stock, par value $0.001 per share (the “common stock”), at a ratio between one-for-two (1:2) and one-for-fifty (1:50) with the ratio to be determined at the discretion of the Board
Biolase Stockholders [Member]
Basis Of Presentation [Line Items]
Common Stock, Par or Stated Value Per Share	$ 0.001		$ 0.001
Reverse Stock Split			a reverse stock split of BIOLASE common stock, par value $0.001 per share (the “common stock”), at a ratio between one-for-two (1:2) and one-for-one hundred (1:100). Immediately after the special meeting, BIOLASE's board of directors (the "Board") approved a one-for-one hundred (1:100) reverse stock split of the outstanding shares of the common stock (the “2023 Reverse Stock Split”).